PARTNER III Trial Begins For Patients With Severe Aortic Stenosis

Patients over 65-years old, who suffer with severe, symptomatic aortic stenosis, identified with low mortality risk in undergoing standard surgical aortic valve replacement, who meet the study criteria, the PARTNER III Trial has begun enrollment at Henry Ford Hospital, the only center in Michigan participating in this study.


This study is the next phase in research on the SAPIEN family of valves, which comes after the valve’s maker, Edwards Lifesciences Corporation, announced that data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement (TAVR) with the SAPIEN XT valve was superior to surgery at one year on a composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation. In addition, the SAPIEN XT valve demonstrated clinical superiority at one year on individual assessments of all-cause mortality and of stroke.


William W. O’Neill, M.D., medical director of the Center for Structural Heart Disease program and a pioneer of TAVR, along with his colleague Gaetano Paone, M.D., division head, Cardiac Surgery, are the primary investigators at Henry Ford Hospital.